Haleon plc
HLN (NYSE)
Haleon plc stands out as a UK-listed consumer healthcare company, recently appearing on Fidelity's list of "most bought shares," making it a noteworthy choice for investors looking for large-cap defensive exposure. With a dividend yield nearing 2% and a solid 5-year return of over 30%, it offers potential for reliable income alongside growth. Analysts have given Haleon a favorable rating of A- with a 12-month price target of $10.20, indicating confidence in its stability and performance.
Pros:
- Defensive exposure in consumer healthcare
- Strong market presence with notable brands
Cons:
- Lower 1-year return compared to historical performance
- Market volatility risk
Haleon plc (HLN) may be a suitable investment for those seeking a blend of steady income and moderate growth in the consumer healthcare sector, particularly for large-cap investors focused on defensive stocks. With a reasonable dividend yield and strong long-term performance, it could appeal to both income-focused and growth-oriented investors looking for stability in their portfolios.